Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S007 - Cosmetics

Friday, February 16; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify new topical agents and cosmetic procedures used to treat and manage patients with pigmentation disorders, skin aging, and hair and scalp disorders.
  • Evaluate the use of nutraceuticals and new cutaneous delivery options to address hair, skin and nail conditions
  • Incorporate new knowledge and clinical pearls into your practice to enhance patient care.

Description

This session will focus on a variety of topics that address the cosmetic concerns of patients. The dermatologic conditions that will be discussed include melasma, post-inflammatory hyperpigmentation, skin aging, and alopecia. Successful management protocols for combining topical agents with aesthetic procedures will be shared, along with how to manage the male aesthetic patient. New technology on skin penetration of active ingredients to enhance efficacy of topicals will be discussed. And finally, all faculty members will provide clinical pearls from their presentations to assist the attendee with providing recommendations for enhanced patient care with optimal outcomes in their clinical setting.

Disclosures

  • Berson, Diane S., MD: Aclaris Therapeutics Inc. – C(H); Allergan, Inc – C(H); Galderma Laboratories, L.P. – A(H); La Roche-Posay Laboratoire Pharmaceutique – A(H); Procter & Gamble Company – C(H); Revance Therapeutics, Inc. – A(H); Sienna Biopharmaceuticals – A(H); Skinfix, Inc. – A(H); Taro Pharm – A(H); TopMD – C(H);
  • Callender, Valerie D., MD: Aclaris Therapeutics Inc. – C(H); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Aerolase – A(H); Allergan, Inc – I(Grants/Research Funding), SP(H); Allergan, Inc. – C(H); Avon Products, Inc. – I(Grants/Research Funding); Cassiopea SpA – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – I(Grants/Research Funding); IntraDerm Pharmaceuticals – A(H); Menlo Therapeutics – A(H); Novan – I(Grants/Research Funding); PCA SKIN – A(H); Pfizer Inc. – SP(H); Promius Pharmaceuticals – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Samumed, LLC – A(H); Sienna Biopharmaceuticals – A(H); Suneva Medical, Inc. – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(H);
  • Draelos, Zoe Diana, MD: Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAÑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding);
  • Farris, Patricia, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – Speaker/Faculty Education(H); ISDIN – A(H); Johnson and Johnson Consumer Products Company – A(H); L'Oreal USA Inc. – A(H); La Roche-Posay Laboratorie Pharmaceutique – A(H); Nutraceutical Wellness, LLC. – A(SO); Regimen MD – F(ST); SkinCeauticals LLC – A(H); SkinMedica, Inc. – A(H);
  • Roberts, Wendy E., MD: Allergan, Inc. – C(H); Cosmetic Bootcamp – A(H); Lumisque – SP(H); SkinCeauticals LLC – A(H); Theraplex – A(NC); TopMD – A(NC);
  • Sadick, Neil S., MD: Allergan, Inc. – C(H), O(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Cassiopea SpA – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H), I(Grants/Research Funding); Derm Advance – SH(SO); DS Laboratories – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Hydropeptide, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Neostrata – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Nutraceutical Wellness, LLC. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Prescriber's Choice – O(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Taub, Amy Forman, MD: Allergan, Inc – A(H); Almirall – A(H); Cutera, Inc. – I(EQ), I(Grants/Research Funding); Exeltis – A(H); Hydrafacial – I(EQ), I(Grants/Research Funding); MediCell Technologies LLC – I(Grants/Research Funding), SH(ST); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sterilis Medical Corporation – SH(ST); Suneva Medical, Inc. – Speaker/Faculty Education(H); Swiss American – A(H); Syneron, Inc. – SP(H);
  • Taylor, Susan C., MD: Aclaris Therapeutics, Inc. – A(H), I(Grants/Research Funding), SP(H); Allergan, Inc – A(H), Speaker/Faculty Education(NC); Beiersdorf, Inc. – A(H), C(H); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H); Galderma Laboratories, LP – Speaker/Faculty Education(H); KGL Skin Study Center – Independent Contractor(S); Neostrata – C(H); Unilever – SP(H);
Schedule
Friday, February 16
9:00 AM
Dr. Callender / Introduction
9:05 AM
Dr. Roberts / What's New in Skin Lightening Agents
9:25 AM
Dr. Taylor / Cosmetic Improvement through Photoprotection
9:45 AM
Dr. Taub / Latest & Greatest Anti-aging Products
10:05 AM
Dr. Berson / Essential Pre- and Post-procedural Cosmetics
10:25 AM
Dr. Draelos / Innovations in Cutaneous Delivery Systems
10:45 AM
Dr. Farris / What's New in the State of the Art Nutraceuticals
11:05 AM
Dr. Sadick / The Growing Trend in Male Aesthetics
11:25 AM
Dr. Callender / Clinical Relevance of Ethnic Hair Cosmetics
11:45 AM
All faculty / Questions & Answers
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 12:00 PM
  • Location
    Ballroom 20B
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Valerie D. Callender, MD, FAAD - Handout
Speakers
  • Amy Forman Taub, MD, FAAD - Handout
  • Diane S. Berson, MD, FAAD - Handout
  • Neil S. Sadick, MD, FAAD
  • Patricia Farris, MD, FAAD - Handout
  • Susan C. Taylor, MD, FAAD
  • Wendy E. Roberts, MD, FAAD
  • Zoe Diana Draelos, MD, FAAD - Handout